Novartis ianalumab receives FDA Breakthrough Therapy designation for Sjögren’s disease
arcticnovartis
Fri, 01/16/2026 – 18:02
Read more about Novartis ianalumab receives FDA Breakthrough Therapy designation for Sjögren’s disease
De…
Novartis to add radioligand therapy manufacturing facility in Winter Park, Florida, fourth in US to serve patients and advance $23 billion investment
arcticnovartis
Fri, 01/09/2026 – 16:32
Read more about Novartis to add radioligand therapy manufa…
Novartis to add radioligand therapy manufacturing facility in Winter Park, Florida, fourth in US to serve patients and advance $23 billion investment
arcticnovartis
Fri, 01/09/2026 – 16:32
Read more about Novartis to add radioligand therapy manufa…
Novartis and US government reach agreement on lowering drug prices in the US
arcticnovartis
Fri, 12/19/2025 – 20:34
Read more about Novartis and US government reach agreement on lowering drug prices in the US
Novartis agrees to tak…
Novartis and US government reach agreement on lowering drug prices in the US
arcticnovartis
Fri, 12/19/2025 – 20:34
Read more about Novartis and US government reach agreement on lowering drug prices in the US
Novartis agrees to tak…
Novartis ianalumab significantly extends disease control in patients with immune thrombocytopenia with only four once-monthly doses
arcticnovartis
Tue, 12/09/2025 – 13:34
Read more about Novartis ianalumab significantly extends disease control in …
Novartis ianalumab significantly extends disease control in patients with immune thrombocytopenia with only four once-monthly doses
arcticnovartis
Tue, 12/09/2025 – 13:34
Read more about Novartis ianalumab significantly extends disease control in …
1 in 4 metastatic breast cancer patients treated with Novartis Kisqali® remain progression-free beyond 4 years
arcticnovartis
Tue, 12/09/2025 – 13:19
Read more about 1 in 4 metastatic breast cancer patients treated with Novartis Kisqali® remain pr…
1 in 4 metastatic breast cancer patients treated with Novartis Kisqali® remain progression-free beyond 4 years
arcticnovartis
Tue, 12/09/2025 – 13:19
Read more about 1 in 4 metastatic breast cancer patients treated with Novartis Kisqali® remain pr…
1 in 4 metastatic breast cancer patients treated with Novartis Kisqali® remain progression-free beyond 4 years
arcticnovartis
Tue, 12/09/2025 – 13:19
Read more about 1 in 4 metastatic breast cancer patients treated with Novartis Kisqali® remain pr…
